Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-6bf8c574d5-t27h7 Total loading time: 0 Render date: 2025-02-23T06:08:08.483Z Has data issue: false hasContentIssue false

Donepezil

Published online by Cambridge University Press:  20 February 2025

K. Ray Chaudhuri ,
Peter Jenner ,
Valentina Leta ,
Shelley Jones  and
Iro Boura
K. Ray Chaudhuri
Affiliation:
King's College London
Peter Jenner
Affiliation:
King's College London
Valentina Leta
Affiliation:
King's College London
Shelley Jones
Affiliation:
King's College London
Iro Boura
Affiliation:
St. George General Hospital of Chania, Crete, Greece
Get access

Summary

Donepezil hydrochloride ((±)-2,3-dihydro-5,6-dimethoxy-2-[[1-phenylmethyl)-4-piperidinyl]methyl]-1H-inden-1-one HCl or (±)-2-[(1-benzyl-4-piperidyl)methyl]-5,6-dimethoxy-1-indanone hydrochloride). It is a white crystalline powder, soluble in water, with a molecular weight of 415.95 and an empirical formula of C24H29NO3.HCl.

Type
Chapter
Information
The Movement Disorders Prescriber's Guide to Parkinson's Disease , pp. 126 - 136
Publisher: Cambridge University Press
Print publication year: 2025

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Suggested Reading

Aarsland, D, Laake, K, Laron, JP, Janvin, C. Donepezil for cognitive impairment in Parkinson’s disease: a randomised controlled study. J Neurol Neurosurg Psychiatry 2002; 72(6): 708–712.CrossRefGoogle ScholarPubMed
Chung, KA, Lobb, BM, Nutt, JG, Horak, FB. Effects of a central cholinesterase inhibitor on reducing falls in Parkinson disease. Neurology 2010; 75(14): 1263–1269.CrossRefGoogle ScholarPubMed
Dubois, B, Tolosa, E, Katzenschlager, R, Emre, M, Lees, AJ, Schumann, G, Pourcher, E, Gray, J, Thomas, G, Swartz, J, Hsu, T, Moline, ML. Donepezil in Parkinson’s disease dementia: a randomized, double-blind efficacy and safety study. Mov Disord 2012; 27(10): 1230–1238.CrossRefGoogle Scholar
Ravina, B, Putt, M, Siderowf, A, Farrar, JT, Gillespie, M, Crawley, A, Fernandez, HH, Trieschmann, MM, Reichwein, S, Simuni, T. Donepezil for dementia in Parkinson’s disease: a randomised, double blind, placebo controlled, crossover study. J Neurol Neurosurg Psychiatry 2005; 76(7): 934–939.CrossRefGoogle ScholarPubMed
Shigeta, M, Homma, A. Donepezil for Alzheimer’s disease: pharmacodynamic, pharmacokinetic, and clinical profiles. CNS Drug Rev 2001; 7(4): 353–368.CrossRefGoogle ScholarPubMed

References

AHFS Drug information 2012. Bethesda: American Society of Health-System Pharmacists. Accessed on 30 June 2022 via www.medicinescomplete.com.Google Scholar
Allen, NE, Canning, CG, Almeida, LRS, Bloem, BR, Keus, SHJ, Löfgren, N, Niewboer, A, Verheyden, GSAF, Yamato, TP, Sherrington, C. Interventions for preventing falls in Parkinson’s disease. Cochrane Database Syst Rev 2022; 6(6): CD011574.Google ScholarPubMed
Bergman, J, Lerner, V. Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson’s disease. Clin Neuropharmacol 2002; 25(2): 107–110.CrossRefGoogle ScholarPubMed
Burns, A, Gauthier, S, Perdomo, C. Efficacy and safety of donepezil over 3 years: an open-label, multicentre study in patients with Alzheimer’s disease. Int J Geriatr Psychiatry 2007; 22(8): 806–812.CrossRefGoogle ScholarPubMed
Donepezil. In: Brayfield, A (Ed.), Martindale: The Complete Drug Reference. London: The Royal Pharmaceutical Society of Great Britain. Accessed on 30 June 2022 via www.medicinescomplete.com.Google Scholar
Donepezil. In: DRUGDEX® System (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. Accessed on 30 June 2022 via http://www.micromedexsolutions.com.Google Scholar
Joint Formulary Committee. British National Formulary (online). London: BMJ Group and Pharmaceutical Press. Accessed on 30 June 2022 via www.medicinescomplete.com.Google Scholar
Leroi, I, Brandt, J, Reich, SG, Lyketsos, CG, Grill, S, Thompson, R, Marsh, L. Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson’s disease. Int J Geriatr Psychiatry 2004; 19(1): 1–8.CrossRefGoogle ScholarPubMed
Minett, TS, Thomas, A, Wilkinson, LM, Daniel, SL, Sanders, J, Richardson, J, Littlewood, E, Myint, P, Newby, J, McKeith, IG. What happens when donepezil is suddenly withdrawn? An open label trial in dementia with Lewy bodies and Parkinson’s disease with dementia. Int J Geriatr Psychiatry 2003; 18(11): 988–993.CrossRefGoogle Scholar
Mueller, C, Rajkumar, AP, Wan, YM, Velayudhan, L, Ffytche, D, Chaudhuri, KR, Aarsland, D. Assessment and management of neuropsychiatric symptoms in Parkinson’s disease. CNS Drugs 2018; 32(7): 621–635.CrossRefGoogle ScholarPubMed
Rogers, SL, Doody, RS, Pratt, RD, Ieni, JR. Long-term efficacy and safety of donepezil in the treatment of Alzheimer’s disease: final analysis of a US multicentre open-label study. Eur Neuropsychopharmacol 2000; 10(3): 195–203.CrossRefGoogle ScholarPubMed
Rolinski, M, Fox, C, Maidment, I, McShane, R ; Cochrane Dementia and Cognitive Improvement Group. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson’s disease dementia and cognitive impairment in Parkinson’s disease. Cochrane Database Syst Rev 2012; 2012(3): CD006504.Google Scholar
Sawada, H, Oeda, T, Kohsaka, M, Umemura, A, Tomita, S, Park, K, Mizoguchi, K, Matsuo, H, Hasegawa, K, Fujimura, H, Sugiyama, H, Nakamura, M, Kikuchi, S, Yamamoto, K, Fukuda, T, Ito, S, Goto, M, Kiyohara, K, Kawamura, T. Early use of donepezil against psychosis and cognitive decline in Parkinson’s disease: a randomised controlled trial for 2 years. J Neurol Neurosurg Psychiatry 2018; 89(12): 1332–1340.CrossRefGoogle ScholarPubMed
Sobow, T. Parkinson’s disease-related visual hallucinations unresponsive to atypical antipsychotics treated with cholinesterase inhibitors: a case series. Neurol Neurochir Pol 2007; 41(3): 276–279.Google ScholarPubMed
Summary of Product Characteristics – Aricept tablets 10 mg. Eisai Ltd. Electronic Medicines Compendium: Aricept tablets 10 mg – summary of product characteristics (SmPC) – (emc). Accessed on 30 June 2022 via www.medicines.org.uk.Google Scholar
Ukai, K, Fujishiro, H, Iritani, S, Ozaki, N. Long-term efficacy of donepezil for relapse of visual hallucinations in patients with dementia with Lewy bodies. Psychogeriatrics 2015; 15(2): 133–137.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Donepezil
  • K. Ray Chaudhuri, King's College London, Peter Jenner, King's College London, Valentina Leta, King's College London, Shelley Jones, King's College London, Iro Boura, St. George General Hospital of Chania, Crete, Greece
  • Book: The Movement Disorders Prescriber's Guide to Parkinson's Disease
  • Online publication: 20 February 2025
  • Chapter DOI: https://doi.org/10.1017/9781009222648.014
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Donepezil
  • K. Ray Chaudhuri, King's College London, Peter Jenner, King's College London, Valentina Leta, King's College London, Shelley Jones, King's College London, Iro Boura, St. George General Hospital of Chania, Crete, Greece
  • Book: The Movement Disorders Prescriber's Guide to Parkinson's Disease
  • Online publication: 20 February 2025
  • Chapter DOI: https://doi.org/10.1017/9781009222648.014
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Donepezil
  • K. Ray Chaudhuri, King's College London, Peter Jenner, King's College London, Valentina Leta, King's College London, Shelley Jones, King's College London, Iro Boura, St. George General Hospital of Chania, Crete, Greece
  • Book: The Movement Disorders Prescriber's Guide to Parkinson's Disease
  • Online publication: 20 February 2025
  • Chapter DOI: https://doi.org/10.1017/9781009222648.014
Available formats
×